Core Viewpoint - Contineum Therapeutics, Inc. (CTNM) has shown a significant price increase of 67% over the past four weeks, with analysts projecting a mean price target of $22.6, indicating a potential upside of 235.8% from the current price of $6.73 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $4.93, where the lowest estimate is $16.00 (137.7% increase) and the highest is $29.00 (330.9% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Agreement - Analysts have shown strong agreement in revising CTNM's earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 2.7% over the past month, with two estimates increasing and no negative revisions [12] - CTNM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Shares of Cars.com (CARS) have increased by 4.7% over the past four weeks, closing at $13.13, with a mean price target of $17.08 indicating a potential upside of 30.1% [1] - The mean estimate consists of six short-term price targets with a standard deviation of $5.02, where the lowest estimate is $12.00 (an 8.6% decline) and the highest is $25.00 (a 90.4% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 0.8% over the past month, with one estimate increasing and no negative revisions [12] - CARS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate the direction of price movement, which appears to be a useful guide [14]

Core Viewpoint - Pharming Group N.V. (PHAR) shares have increased by 17.9% in the past four weeks, closing at $12.48, with a mean price target of $30.67 indicating a potential upside of 145.8% [1] Price Targets and Analyst Consensus - The average price target consists of three estimates ranging from a low of $14.00 to a high of $41.00, with a standard deviation of $14.57, suggesting a potential increase of 12.2% to 228.5% from the current price [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement, which can be a useful starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about PHAR's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, two estimates have been revised upward, leading to a 75% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - PHAR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a good guide for potential investment [14]

Core Viewpoint - TTM Technologies (TTMI) has seen a 2.9% increase in share price over the past four weeks, closing at $43.85, with analysts suggesting a potential upside of 29.4% based on a mean price target of $56.75 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $2.22, indicating a range of estimates from a low of $55.00 (25.4% increase) to a high of $60.00 (36.8% increase) [2][9]. - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can be a useful starting point for further research [2][9]. Earnings Estimates and Analyst Sentiment - There is increasing optimism among analysts about TTMI's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [11][12]. - The Zacks Consensus Estimate for the current year has risen by 5% over the past month, with three estimates increasing and no negative revisions [12][13]. - TTMI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]. Caution on Price Targets - While consensus price targets are a common metric for investors, relying solely on them for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][7][10].

Core Viewpoint - Thryv Holdings, Inc. (THRY) shows significant upside potential with a mean price target of $21.4, indicating a 60.2% increase from the current price of $13.36 [1] Price Targets and Analyst Consensus - The average price target consists of five estimates ranging from a low of $16.00 to a high of $26.00, with a standard deviation of $4.1, suggesting variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 19.8%, while the highest suggests a 94.6% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about THRY's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 27%, with no negative revisions [12] - THRY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Ikena Oncology, Inc. (IMA) shares have increased by 2.4% over the past four weeks, closing at $16.6, with a mean price target of $132.05 indicating a potential upside of 695.5% [1][2] - The mean estimate includes three short-term price targets with a standard deviation of $125.33, where the lowest estimate suggests an increase of 189.3% and the highest indicates a surge of 1563.3% to $276.11 [2] - Analysts show strong agreement on IMA's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for IMA has increased by 51.5% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - IMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Group 1 - Forge Global Holdings, Inc. (FRGE) closed at $23, with a 26.8% gain over the past four weeks, and has a mean price target of $33.6, indicating a 46.1% upside potential [1] - The average price targets range from a low of $18.00 to a high of $60.00, with a standard deviation of $15.65, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.8% over the past month, with two estimates going higher and no negative revisions [12] - FRGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [14]

Group 1 - Precision Drilling (PDS) closed at $53.58, with a 7.9% gain over the past four weeks, and a mean price target of $70.3 indicating a 31.2% upside potential [1] - The average price targets from analysts range from a low of $51.70 to a high of $87.60, with a standard deviation of $10.04, suggesting variability in estimates [2] - Analysts show strong agreement on PDS's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - The Zacks Consensus Estimate for PDS has increased by 20.8% over the past month, with no negative revisions, reflecting growing optimism about the company's earnings prospects [12] - PDS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Core Viewpoint - EZcorp (EZPW) shows potential for significant upside, with a mean price target of $21 indicating a 42.5% increase from its current price of $14.74 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.37, suggesting variability among analysts [2] - The lowest estimate is $17.00, indicating a 15.3% increase, while the highest estimate is $25.00, suggesting a 69.6% increase [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about EZPW's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 2.9% rise in the Zacks Consensus Estimate [12] - EZPW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Core Viewpoint - Amicus Therapeutics (FOLD) shares have increased by 12.9% recently, with a mean price target of $16.27 suggesting a potential upside of 138.2% from the current price of $6.83 [1] Price Targets and Analyst Consensus - The average of 11 short-term price targets ranges from a low of $9.00 to a high of $22.00, with a standard deviation of $3.85, indicating variability among analysts [2] - The lowest estimate suggests a 31.8% increase, while the highest points to a 222.1% upside [2] - A low standard deviation indicates a strong agreement among analysts regarding the price movement of FOLD [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about FOLD's earnings prospects, with a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 33.3%, with no negative revisions [12] - FOLD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of FOLD's potential gains, the implied direction of price movement appears to be a useful guide [14]